Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C virus genotype 1 infection in China

被引：0
|
作者：
Li, Fan [1 ]
Chen, Guofeng [1 ]
Shao, Qing [1 ]
Ji, Dong [1 ]
Li, Bing [1 ]
Li, Zhongbin [1 ]
Liu, Jialiang [1 ]
Liu, Chunxiao [1 ]
Wang, Tingting [1 ]
Wang, Qiaomin [1 ]
Chen, Jing [2 ]
Wu, Vanessa [2 ]
Wong, April [2 ]
Wang, Cheng [2 ]
Wang, Yudong [2 ]
Lau, George K. [1 ,2 ]
机构：
[1] 302 Hosp, Liver Fibrosis Diag & Treatment Ctr, Beijing, Peoples R China
[2] Humanity & Hlth Med Grp, Gastroenterol & Hepatol, Hong Kong, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1537
引用
收藏
页码：959A / 960A
页数：2
相关论文
共 50 条
  • [1] Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in US Incarcerated Populations A Cost-Effectiveness Analysis
    Liu, Shan
    Watcha, Daena
    Holodniy, Mark
    Goldhaber-Fiebert, Jeremy D.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (08) : 546 - U43
  • [2] Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
    Zhou, Hui Jun
    Cao, Jing
    Shi, Hui
    Naidoo, Nasheen
    Semba, Sherehe
    Wang, Pei
    Fan, Yi Fan
    Zhu, Shui Cheng
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [3] Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C
    Miguel, Ramon San
    Gimeno-Ballester, Vicente
    Blazquez, Antonio
    Mar, Javier
    [J]. GUT, 2015, 64 (08) : 1277 - U122
  • [4] The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection
    Linas, Benjamin P.
    Barter, Devra M.
    Morgan, Jake R.
    Pho, Mai T.
    Leff, Jared A.
    Schackman, Bruce R.
    Horsburgh, C. Robert
    Assoumou, Sabrina A.
    Salomon, Joshua A.
    Weinstein, Milton C.
    Freedberg, Kenneth A.
    Kim, Arthur Y.
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 162 (09) : 619 - U220
  • [5] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Loomis, T. P.
    Mole, L. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) : 559 - 573
  • [6] Cost-Effectiveness of Sofosbuvir-Based Triple Therapy for Untreated Patients With Genotype 1 Chronic Hepatitis C
    Petta, Salvatore
    Cabibbo, Giuseppe
    Enea, Marco
    Macaluso, Fabio Salvatore
    Plaia, Antonella
    Bruno, Raffaele
    Gasbarrini, Antonio
    Craxi, Antonio
    Camma, Calogero
    [J]. HEPATOLOGY, 2014, 59 (05) : 1692 - 1705
  • [7] Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
    Younossi, Z. M.
    Park, H.
    Saab, S.
    Ahmed, A.
    Dieterich, D.
    Gordon, S. C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) : 544 - 563
  • [8] Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
    Zhang, Sai
    Bastian, Nathaniel D.
    Griffin, Paul M.
    [J]. BMC GASTROENTEROLOGY, 2015, 15
  • [9] Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
    Sai Zhang
    Nathaniel D. Bastian
    Paul M. Griffin
    [J]. BMC Gastroenterology, 15
  • [10] Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada
    Moshyk, A.
    Martel, M. -J.
    Monfared, A. A. Tahami
    Goeree, R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (02) : 181 - 192
12345